KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Moderna (MRNA) Accumulated Depreciation & Amortization (2016 - 2025)

Moderna (MRNA) has disclosed Accumulated Depreciation & Amortization for 10 consecutive years, with $211.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 14.05% to $211.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $211.0 million through Dec 2025, up 14.05% year-over-year, with the annual reading at $211.0 million for FY2025, 14.05% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $211.0 million at Moderna, up from $51.0 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $617.0 million in Q4 2023, with the low at $15.0 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $144.8 million, with a median of $92.0 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization soared 762.5% in 2021, then tumbled 70.02% in 2024.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $232.0 million in 2021, then surged by 50.0% to $348.0 million in 2022, then skyrocketed by 77.3% to $617.0 million in 2023, then tumbled by 70.02% to $185.0 million in 2024, then grew by 14.05% to $211.0 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $211.0 million, $51.0 million, and $94.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.